Overview

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Status:
Not yet recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Beijing Friendship Hospital

Treatments:

Albumin-Bound Paclitaxel
Apatinib
Paclitaxel